LIFE TECHNOLOGIES
LIVE

Serial Number

77592675

Owner

LIFE TECHNOLOGIES CORPORATION

Attorney

Kenya L. Williams

First Use Date

Dec 1, 1986

Filing Date

Oct 14, 2008

Add to watchlist:

No watchlists yet
View on USPTO

LIFE TECHNOLOGIES Trademark

Serial Number: 77592675 • Registration: 4422138

LIFE TECHNOLOGIES is a trademark filed by LIFE TECHNOLOGIES CORPORATION on October 14, 2008. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 37 (Building & Construction), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 16 (Paper Goods). The application is currently registered and active.

Owner Contact Info

LIFE TECHNOLOGIES CORPORATION (518 trademarks)

5823 Newton Drive
Carlsbad, CA 92008

Entity Type: 03

INVITROGEN CORPORATION (143 trademarks)

1600 FARADAY AVENUE
CARLSBAD, CA 92008

Entity Type: 03

Trademark Details

Filing Date

October 14, 2008

Registration Date

October 22, 2013

First Use Anywhere

December 1, 1986

First Use in Commerce

December 1, 1986

Published for Opposition

November 2, 2010

Goods & Services

Computer software used for the collection, organization, analysis, integration and communication of scientific data; computer software used to operate laboratory instruments; laboratory instruments, namely, nucleic acid sequencers and synthesizers, genetic analyzers, [ thermal cyclers, cytometers, protein and peptide synthesizers, mass spectrometers and chromatographs, laboratory instruments for preparation of nucleic acid samples, laboratory robots; laboratory supplies, namely, racks, vials, caps, septa, needles, bottles, flasks, ] [ filters, ] [ tubes, and seals, plastic tray covers, micro plates, pipette tips, reagent reservoirs, optical heat field covers, plastic cards, and plastic capillary arrays; all ] for scientific and research use and diagnostics use [ ; computer software for the construction of recombinant DNA molecules in the fields of molecular biology and genetics, building of functional or restriction maps, describing recombinant molecules, and obtaining the exact nucleotide sequences of recombinant DNA molecules; and computer software for use in database management in the fields of molecular biology and genetics that may be downloaded from a global computer network and computer software for use in database management in the fields of molecular biology and genetics; magnetic particle concentrator to be used with magnetic particle-based biomedical separations; full line of laboratory apparatus for protein and nucleic acid electrophoresis; ] [ optical filters for wavelengths of light; ] [ detectors using light sources for identifying proteins, nucleic acids, cellular metabolites, carbohydrates, viruses, bacteria and/or eukaryotic cells; analyzers for laboratory uses for identifying proteins, nucleic acids, cellular metabolites, carbohydrates, viruses, bacteria and/or eukaryotic cells; laboratory instruments for performing automated washing, dispensing, hybridization, and imaging of chip based sequence specific oligonucleotides; fluorometer or spectrophotometer used for detection and quantitation of DNA, RNA, protein or other analytes in solution, detachable power cord; ] [ detachable Universal Serial Bus (USB) data cord; scientific apparatus, namely, assay tubes; ] [ software for analysis or results, all for use with a fluorometer or spectrophotometer; laboratory instrument for the detection of pathogens and/or toxins in a sample; laboratory equipment, namely, apparatus in the nature of biochips for identification, detection of presence of biological or chemicals in a sample and determination of physical or chemical properties of a sample, synthesizers for making polymer arrays and parts therefor, and hybridization stations for making fluidic and microfluidic devices ]

[ Newsletters on products for scientific research ]

Microbiological culture media, animal blood sera, mammalian and insect cells, mammalian and insect cell culture media and cell culture reagents, all for medical diagnostic use [ ; diagnostic biochemical and biological reagents for medical purposes in the detection or treatment of illnesses; chemical reagents for medical uses in the detection of pathogens and/or toxins in veterinary samples; ] [ pharmaceuticals preparations and compositions for therapeutic use, namely, for expanding, selecting and deleting cells of the immune systems; ] [ preparations and compositions for therapeutic use, namely, for activating cells of the immune systems; ] [ pharmaceutical preparations for use in the treatment of cancer, infectious diseases and immunodeficiencies; ] [ antibody-conjugated beads, antibody-conjugated micro-beads and antibody-conjugated microspheres for promoting a therapeutic effect on the body ]

[ Installation, maintenance and repair of laboratory instruments for scientific, research, medical, and diagnostics use; Installation, maintenance and repair of computer hardware for scientific, research, medical, and diagnostics use ]

Reagents and kits comprised of reagents for scientific or medical research use; diagnostic reagents and kits comprised of diagnostic reagents for scientific or medical research use; [ cellular pathway exploration tools, namely, enzyme-linked immunosorbent assay (ELISA), kinase activity assays, protein arrays, recombinant proteins and antibodies all for analysis of multiple proteins and pathways in the field of scientific research; human, mouse and rat markers and antibodies conjugated to fluorescent chemical dyes, and human, mouse and rat markers and antibodies conjugated to proteins, namely, cytokines and chemokines, all for use in flow cytometry; ] culture media for non-medical use, culture growth supplements in the nature of biochemicals, reagents for use in cultures; all for use in scientific, laboratory, and medical research; [ in vitro ADME cell products, namely, fresh and cryopreserved hepatocytes and liver subcellular fractions, and transporters derived from a variety of species, including human, non-human primate, dog, rat and mouse for scientific research; magnetic particle-based biomedical separation systems comprising magnetizable polymer beads, the attached antibody and the magnetic particle concentrator for separating a specific selected cell population from a larger, more complex cell population for scientific research; biological and biochemical preparations, namely, reagents and kits consisting of proteins, PCR fragments, cDNA libraries, vectors, enzymes, molecules, clones, genes, cell, recombination proteins and sites, restriction enzymes, primers, plasmids, and reagents all for scientific medical research, or research use. ] Microbiological culture media, animal blood sera, mammalian and insect cells, mammalian and insect cell culture media and cell culture reagents, all for scientific or medical research use [ ; full line of kits consisting primarily of one or more of the following, namely, protein arrays, nucleic acids, hormones, purification supports, resins, cells, gels, probes, buffers, stains and associated reagents and devices for the expression, amplification, purification and analysis of biological samples; fluorescent chemicals for use in scientific research; electrophoresis gel and chromatography chemicals, buffers, and solutions for scientific research; research and diagnostic biochemical and biological reagents, other than for medial or veterinary purposes, for agricultural, ecological, DNA typing, food processing and research laboratories; reagents and assays used for detection and quantitation of DNA, RNA, protein or other analytes in solution, sold individually or in kits for research use; chemical reagents for non-medical purposes for the detection of pathogens and/or toxins in environmental samples; synthetic DNA for use in biotechnology; synthetic DNA and molecules used as DNA molecular weight standards for use in the biotechnology field; nucleotide arrays for scientific research; biochemical reagents for scientific research; buffers for use in analytical chemistry all for scientific and medical research use; chemicals used for medical purposes, namely, reagents containing ligands, effector molecules and antibodies all for scientific or medical research use; antibody-conjugated micro-beads and antibody-conjugated microspheres all for scientific and medical research use and for activation of immune system cells; cell culture reagents for medical laboratory use; fluorescent chemical dyes for clinical medical laboratory use, namely, for measurement of pH in medical laboratories ]

[ Consultation in the field of medicine, health and pharmaceuticals ]

[ Providing an on-line computer database featuring information in the field of scientific and medical research; research in the fields of science, technology, medicine and health, namely, nucleic acid sequencing, analysis and synthesis of oligonucleotides and other molecules for others for use in life science research and biotechnology research; consultation services in the field of science and technology consultation in the field of nucleic acid sequencing, analysis and synthesis of igonucleotides and other molecules for others for use in life science research and biotechnology research; computer services, namely, providing temporary use of on-line non-downloadable software for accessing and analyzing information in the field of science, technology, medicine, health and public policy; medical, research and laboratory diagnostic services in the field of nucleic acid sequencing, analysis and synthesis of oligonucleotides and other molecules for others for use in life science research and biotechnology research; product development for others; laboratory services, namely, nucleic acid sequencing, synthesis and analysis, analysis and synthesis of oligonucleotides and other molecules for others for use in life science research and biotechnology research; installation, maintenance and repair of computer software for scientific, research, medical, and diagnostic use; nucleic acid analysis; genetic research, namely, gene discovery; genetic disease research, genomics and gene expression research and development; pharmacokinetic research services; proteomics research services; gene identification, gene cloning, gene expression, gene mapping, electrophoresis, protein purification and analysis, and protein interaction detection all for scientific purposes; medical and scientific research; medical and scientific research for the development and commercialization of cell-based therapeutic immune system stimulators and enhancers to treat cancer and infectious diseases; technical research and consultation related thereto in the fields of pharmaceuticals, medicine, biological sciences, immunotherapy, and medical devices; development of new products in the fields of pharmaceuticals, medicine, biological sciences, immunotherapy, and medical devices for others; medical laboratory services; research and development for new immunotherapy products for others; biopharmaceutical research and development; scientific research services; medical laboratory testing and diagnostic services for others in the fields of science and research related thereto; scientific research, namely, developing customized microbiological, mammalian, and insect culture media, media formulations, and cell culture reagents, and evaluating culture media for others; contract laboratory services, namely, conducting drug-drug interaction studies, drug metabolism studies and hepatotoxicity studies, namely, enzyme induction and inhibition, reaction phenotyping, metabolite stability and profiling, and P-gp assays, and consulting services related thereto ]

Filing History

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Aug 12, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 12, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 12, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 12, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 12, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 12, 2025 COAR
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Mar 22, 2024 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Mar 22, 2024 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Mar 22, 2024 89AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 22, 2024 APRE
TEAS SECTION 8 & 9 RECEIVED
Oct 23, 2023 E89R
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 10, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 10, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 10, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 10, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 10, 2023 COAR
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Oct 22, 2022 REM2
AMENDMENT UNDER SECTION 7 - PROCESSED
Apr 22, 2021 A7OK
TEAS SECTION 7 REQUEST RECEIVED
Apr 16, 2021 ES7R
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Nov 23, 2019 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Nov 23, 2019 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 23, 2019 APRE
TEAS SECTION 8 & 15 RECEIVED
Oct 18, 2019 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 22, 2018 REM1
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 23, 2014 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 23, 2014 REAP
REGISTERED-PRINCIPAL REGISTER
Oct 22, 2013 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sep 14, 2013 SUNA
LAW OFFICE REGISTRATION REVIEW COMPLETED
Sep 13, 2013 REGV
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Sep 5, 2013 CNPR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 14, 2013 EXRA
STATEMENT OF USE PROCESSING COMPLETE
Aug 13, 2013 SUPC
SOU EXTENSION 5 GRANTED
Aug 13, 2013 EX5G
USE AMENDMENT FILED
Aug 12, 2013 IUAF
SOU EXTENSION 5 FILED
Aug 12, 2013 EXT5
SOU TEAS EXTENSION RECEIVED
Aug 12, 2013 EEXT
TEAS STATEMENT OF USE RECEIVED
Aug 12, 2013 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 25, 2013 EXRA
SOU EXTENSION 4 GRANTED
May 24, 2013 EX4G
SOU EXTENSION 4 FILED
May 1, 2013 EXT4
SOU TEAS EXTENSION RECEIVED
May 1, 2013 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 26, 2012 EXRA
SOU EXTENSION 3 GRANTED
Oct 25, 2012 EX3G
SOU EXTENSION 3 FILED
Oct 23, 2012 EXT3
SOU TEAS EXTENSION RECEIVED
Oct 23, 2012 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 10, 2012 EXRA
SOU EXTENSION 2 GRANTED
May 9, 2012 EX2G
SOU EXTENSION 2 FILED
May 1, 2012 EXT2
SOU TEAS EXTENSION RECEIVED
May 1, 2012 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 28, 2011 EXRA
SOU EXTENSION 1 GRANTED
Oct 27, 2011 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 26, 2011 AITU
SOU EXTENSION 1 FILED
Oct 25, 2011 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 25, 2011 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 2, 2011 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 2, 2011 REAP
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 3, 2011 NOAM
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Mar 18, 2011 ETOP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 1, 2011 TCCA
EXTENSION OF TIME TO OPPOSE RECEIVED
Dec 2, 2010 ETOF
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Nov 3, 2010 ASCK
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 2, 2010 NPUB
PUBLISHED FOR OPPOSITION
Nov 2, 2010 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 25, 2010 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 23, 2010 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 3, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 2, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 2, 2010 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 15, 2010 GNRN
NON-FINAL ACTION E-MAILED
Mar 15, 2010 GNRT
NON-FINAL ACTION WRITTEN
Mar 15, 2010 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 19, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 19, 2010 CRFA
ASSIGNED TO LIE
Jan 25, 2010 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 14, 2010 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 16, 2009 GNRN
NON-FINAL ACTION E-MAILED
Jul 16, 2009 GNRT
NON-FINAL ACTION WRITTEN
Jul 16, 2009 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 25, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 24, 2009 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 24, 2009 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 21, 2009 GNRN
NON-FINAL ACTION E-MAILED
Jan 21, 2009 GNRT
NON-FINAL ACTION WRITTEN
Jan 21, 2009 CNRT
ASSIGNED TO EXAMINER
Jan 13, 2009 DOCK
NEW APPLICATION ENTERED
Oct 17, 2008 NWAP